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he anxiety disorders,including panic disorder
(PD),generalized anxiety disorder (GAD),social anxi-
ety disorder (SAD), and posttraumatic stress disorder
(PTSD),are among the disabling medical disorders.They
frequently begin early in life, are characterized by
repeated episodes and chronicity,and can have serious
medical and psychological consequences leading to func-
tional disability in many patients.
These disorders are currently diagnosed using standard-
ized diagnostic criteria (Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition [DSM-IV] and
International Classification of Diseases [ICD-10]),which
are almost exclusively based upon phenomenology,and
not genetics,etiology,or pathophysiology.
1This has ham-
pered progress in some spheres,since these disorders,as
currently diagnosed,are often comorbid with each other,
and advances in preclinical and clinical neuroscience sug-
gest that there may be overlapping circuit and neuro-
chemical modulation of behaviors that characterize one or
more of these disorders.
2
Clinical neurobiological research pertaining to these anx-
iety disorders has been dominated by investigations
directed toward identifying dysfunctional neural circuits
and neurochemical systems,vulnerability genes,and psy-
chopharmacology.While this makes obvious sense,there
has been far too little clinical research on neurobiological
factors that may convey protection from anxiety disorders
and promote psychobiological resilience in the face of
stress that commonly increases psychopathology.This type
of research may facilitate the discovery of preventative
approaches to anxiety disorders. Further, by reducing
reliance on the standardized diagnostic classification sys-
tems noted above,while increasing our knowledge of the
neural circuits that mediate behavioral and psychological
responses to threat,fear conditioning,reward behavior,
and social attachment—circuits relevant to essentially all
of the anxiety disorders—the opportunity exists to estab-
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T
Much of the research on the neurobiology of human
anxiety disorders has focused on psychopathological
abnormalities in patients with anxiety disorders. While
this line of research is obviously important, more inves-
tigation is needed to elucidate the psychobiology of
resilience to extreme stress. Study of the psychobiology
of resilience has the potential to identify neurochemi-
cal, neuropeptide, and hormonal mediators of vulnera-
bility and resilience to severe stress. In addition, the rel-
evance of neural mechanisms of reward and motivation,
fear responsiveness, and social behavior to character
traits associated with risk and resistance to anxiety dis-
orders may be clarified. These areas of investigation
should lead to improved methods of diagnosis, novel
approaches to prevention, and new targets for antianx-
iety drug discovery.
© 2003, LLS SAS Dialogues Clin Neurosci. 2003;5:207-221.lish a “new neurobiology”of anxiety disorders that may
result in a radically different classification system that is
based upon etiology and pathophysiology.
In this context,this review will consider anxiety disorders
from the perspective of the psychobiological mechanisms
of both resilience and vulnerability to extreme stress.
Implications for an improved diagnostic system,discovery
of genes related to resilience and vulnerability,and the dis-
covery of novel therapeutics related to prevention and
treatment will be highlighted.
Psychological characteristics of resilience
The majority of research on resilience in the face of
adversity focuses on early childhood and adolescence.
Investigations of the effects of war, family violence,
poverty,and natural disasters on children have revealed
a consistent pattern of individual characteristics associ-
ated with successful adaptation.These include good intel-
lectual functioning,effective self-regulation of emotions
and attachment behaviors, positive self concept, opti-
mism,altruism,a capacity to convert traumatic helpless-
ness into learned helpfulness,and an active coping style
in confronting a stressor.
3-5
In contrast to the research in children, studies of
resilience in adults has focused on studies of men in com-
bat. However, this work is applicable to other profes-
sions,such as firefighters and police,in which danger is
ever present and effective action under stress is imper-
ative.Characteristics associated with high performance
under stress include altruism,compassion,and an ability
to function effectively despite high levels of fear.These
include an ability to bond with a group with a common
mission,a high value placed in altruism,and the capacity
to tolerate high levels of fear and still perform effectively.
Most courageous individuals are not fearless,but are will-
ing and able to approach a fear-inducing situation despite
the presence of subjective fear and psychophysiological
disturbance.
6-8
Some individuals are capable of extraordinary resilience
in the context of one type of situation (those involving
physical danger such as combat),but not another (those
involving emotional abuse and neglect).It is likely that dif-
ferent psychological attributes are required for successful
adaptation depending upon the circumstances.
Selected psychological characteristics related to
the risk of anxiety disorders
Several psychological factors have been associated with
increased risk for anxiety disorders.Among the most inten-
sively researched has been the concept of anxiety sensitiv-
ity (AS).AS has been defined as the individual response to
physiological alterations associated with anxiety and fear.
Patients with anxiety disorders have exaggerated psycho-
logical reactions that are reflective of misinterpretation of
bodily cues such that the patient misperceives these sensa-
tions inappropriately as being harmful and dangerous,lead-
ing in a circular fashion to increased anxiety and fear.AS is
associated with a selective cognitive bias toward threat.
9AS
predicts the frequency and intensity of panic attacks.There
is evidence that parental concern about anxiety increases
AS in their children.AS appears to be a trait abnormality
and increases the risk for anxiety disorders.Increased AS
can be reduced by cognitive behavioral therapy.
10
Kagan,Rapee,and others have investigated whether spe-
cific temperamental factors affect the development of anx-
iety disorders in children and adolescents.
11-17 It has
become clear that some children have an inherited neu-
robiological predisposition to increased physiological reac-
tivity and anxious symptoms in the context of unfamiliar
environments and,consequently,are more vulnerable to
one or more of the anxiety disorders.
14 Kagan estimates
that roughly 20% of healthy children are born with such a
temperamental bias termed behavioral inhibition (BI).
Environmental influences intersect with temperament and
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Selected abbreviations and acronyms
AS anxiety sensitivity
BI behavioral inhibition
CeA central nucleus of the amygdala
CRH corticotropin-releasing hormone
CS conditioned stimuli
DHEA dehydroepiandrosterone
GAD generalized anxiety disorder
LC locus ceruleus
LTP long-term potentiation
NAc nucleus accumbens
NE norepinephrine
NPY neuropeptide Y
PD panic disorder 
PFC prefrontal cortex
PTSD posttraumatic stress disorder
SAD social anxiety disorder
US unconditioned stimuli
VTA ventral tegmental areaby adolescence approximately one-third of BI children
ultimately exhibit indications of serious social anxiety.
18 In
a recent study by Biederman and colleagues,BI was asso-
ciated with SAD in children whose parents had PD.
19
These data suggest that parental PD and childhood could
be used to identify children at high risk for SAD.Rapee
believes that inhibited temperament in preschool years is
a relatively strong predictor of anxiety disorders in mid-
dle childhood,a reasonable predictor of adolescent anxi-
ety disorders,and a weak to moderate predictor of adult
anxiety disorders.
11
Kagan has also suggested that BI children may be espe-
cially susceptible to anxiety or PTSD after threatening
events.
14 Studies of children who developed anxiety fol-
lowing a traumatic event suggest that a prior avoidant per-
sonality was a major risk factor.
19 However,it is notewor-
thy that the majority of BI children do not develop anxiety
disorders in later adult life,indicating the importance of
other intervening biological and genetic factors.
The presence of BI and evidence of insecure attachment
to caregivers both contribute to the variance in the
expression of anxious symptoms in preschoolers.
20This
may be related to the findings that parental overprotec-
tion,excessive criticism,and lack of warmth are risk fac-
tors for the appearance of anxiety disorders in childhood.
Environmental risk factors for the development of anx-
iety disorders (as well as depression) include poverty,
exposure to violence,social isolation,and repeated losses
of interpersonal significance.
The neurobiological phenotype and genotype associated
with temperamental risk factors for anxiety disorders,
such as AS and BI, remain to be precisely defined.
However,a recent imaging study by Schwartz and col-
leagues revealed the presence of amygdala hyperactivity
in adult subjects with a history of BI as children.
21
Given the clinical importance of the interaction between
genetic and environmental risk factors,research is needed
to identify the mediating neurobiological factors.The neu-
rochemical responses to stressful life events may account,
in part,for the ability of severe stress to increase the risk
of anxiety disorders in vulnerable individuals.
Neurochemical response patterns to
extreme stress: resilience and vulnerability
to anxiety disorders
A number of neurotransmitters,neuropeptides,and hor-
mones have been linked to the acute psychobiological
response to stress and the longer-term psychiatric out-
come.We will review the role of those neurotransmitters,
neuropeptides,and hormones that have been shown to be
significantly altered by psychological stress,have impor-
tant functional interactions,and mediate the neural mech-
anisms and neural circuits relevant to the regulation of
reward,fear conditioning,and social behavior.An attempt
will be made to identify a putative neurochemical profile
that characterizes psychobiological resilience and has pre-
dictive value as to whether or not stress will increase the
risk of anxiety disorders.
Cortisol and DHEA
Psychological stress has been demonstrated to increase
the synthesis and release of cortisol.Cortisol has many dif-
ferent functions including mobilization of energy stores,
increased arousal,vigilance,focused attention,and mem-
ory formation,inhibition of the growth and reproductive
system, and containment of the immune response.The
behavioral effects of cortisol are due,in part,to regulatory
effects on the hippocampus,amygdala,and prefrontal cor-
tex (PFC).
22,23 Glucocorticoids enhance amygdala activity,
possibly as a consequence of increased corticotropin-
releasing hormone (CRH) function in the central nucleus
of the amygdala (CeA).
24-26 Cortisol also increases the
effects of CRH on conditioned fear,
27 and facilitates the
encoding of emotion-related memory.
28 Many of the
effects of cortisol, particularly those outside the hypo-
thalamo-pituitary-adrenal (HPA) axis,are mediated via
an interaction with the glucocorticoid receptor (GR).A
role for the GR in anxiety modulation is suggested by
studies indicating that GR knockout mice have a pheno-
type characterized by reduced anxiety responses to stress.
29
Another adrenal steroid that is intimately involved in the
stress response is dehydroepiandrosterone (DHEA).
DHEA is secreted with cortisol in response to fluctuating
adrenocorticotropic hormone (ACTH) levels.
30There is
evidence that DHEA possesses antiglucocorticoid and
antiglutamatergic properties in the brain.
31-33 Since periph-
erally produced DHEA is thought to be a major source of
brain DHEA,it is likely that within the brain regionally
specific metabolism of DHEA may ultimately control the
nature of DHEA’s effects on cognition and behavior.
34
There are emerging data that DHEA may be involved in
the reason why some people are resilient in the face of
psychological stress.In patients with PTSD (Rasmussen
AM,unpublished data),decreased DHEA reactivity to
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PTSD.In a recent study of elite special operations soldiers,
negative correlations between DHEA/cortisol ratios and
dissociation during prolonged and extreme training stress,
and between DHEA or DHEA-sulfate (DHEA-S) levels
in the recovery period and better overall performance
were observed.
35 In addition, there are several studies
reporting negative associations between plasma DHEA
levels and depressive symptoms and the antidepressant
effects of DHEA.
36-39 Future studies need to focus possible
mechanisms underlying the effects of DHEA
40,41 and most
importantly possible roles for DHEA in other anxiety dis-
orders aside from PTSD.
Corticotropin-releasing hormone
CRH is another important mediator of the stress
response,
42 as reflected by the stress-induced release of
CRH from the hypothalamus into the hypthalamo-pitu-
itary portal circulation resulting in activation of HPA axis
and the increased release of cortisol and DHEA. The
extrahypothalamic effects of CRH are also important.The
following brain regions have neurons that contain CRH:
the PFC,the cingulate cortex,the CeA,the bed nucleus of
the stria terminalis (BNST), the nucleus accumbens
(NAc), the periaqueductal gray (PAG), and brain stem
nuclei,such as the major norepinephrine (NE)–contain-
ing nucleus, the locus ceruleus (LC) and the serotonin
nuclei in the dorsal and median raphe.
43
Amygdala CRH neuronal hyperactivity may mediate fear-
related behaviors, while excessive cortical CRH may
reduce reward expectation. Early life stress results in
chronic elevation of brain CRH activity and the individ-
ual response to heightened CRH function may depend
upon the social environment, past trauma history, and
behavioral dominance.
44The CRH-1 receptor has been
linked to the anxiogenic actions of CRH.CRH-1 recep-
tor knockout mice have reduced anxiogenic responses to
stress and CRH-1 receptor antagonist drugs have anxi-
olytic effects in laboratory animals.
45 In contrast,prelimi-
nary data suggest that stimulation of the CRH-2 receptor
results in reduced anxiety-related behaviors.
46
Research into the role of CRH in the pathophysiology
of anxiety disorders has been limited by the lack of
CRH receptor ligands useful for brain imaging in human
subjects. Increased cerebrospinal fluid (CSF) levels of
CRH have been linked to PTSD by several studies.
47,48
Psychobiological resilience may be related to an ability
to restrain the initial CRH response to acute stress.Too
few investigations have been conducted in other anxiety
disorder patient groups to form definitive conclusions
regarding the pathophysiological role of CRH.
LC-NE system
Activation of the LC results in increased release of NE
in LC projection regions,such as the amygdala,PFC,and
the hippocampus.The LC is activated by a variety of
endogenous (hypoglycemia, decreased blood volume,
decreased blood pressure,altered thermoregulation,and
distention of colon and bladder) and exogenous (envi-
ronmental stress, threat) stressors. Such activation is
likely important to survival from a life-threatening situ-
ation and serves as a general alarm function.
49
The ability of acute stress to activate both the HPA and
LC-NE systems facilitates the encoding and relay of
aversively charged emotional memories beginning in the
amygdala.The amygdala and the LC inhibit the PFC,
and stimulate hypothalamic CRH release.These feed-
back loops among the PFC, amygdala, hypothalamus,
and brain stem noradrenergic neurons contain the ele-
ments for a sustained and powerful stress response.
22
Psychological resilience and reduced anxiety responses
to stress are probably associated with LC-NE system
activation,which stays within a window of adaptive ele-
vation required to respond to danger,but not so high as
to produce incapacity, anxiety, and fear. If unchecked,
persistent hyperresponsiveness of the LC-NE system
will contribute to chronic anxiety,fear,intrusive memo-
ries, and increased risk of hypertension and cardiovas-
cular disease.In some patients with PD and PTSD,there
is evidence of heightened LC-NE activity.
50-53 More
research is needed to determine the role of the LC-NE
system in GAD and SAD.
There is preliminary evidence that β-receptor antagonist
treatment shortly after traumatic stress exposure may
have beneficial and perhaps preventative effects.
54,55 α1
receptor blockade with prazosin has been shown to reduce
nightmares and associated sleep disturbances in PTSD.
56
Neuropeptide Y
Neuropeptide Y (NPY) is among the most abundant
neuropeptides in mammalian brain with high concen-
trations in the LC
57;paraventricular nucleus of the hypo-
thalamus
58;septohippocampal neurons
59;nucleus of soli-
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60 Moderate levels
are found in the amygdala, hippocampus, cerebral cor-
tex,basal ganglia,and the thalamus.
61
NPY has been shown to have anxiolytic activity and to
impair the consolidation of memories.These effects are
mediated at least, in part, by NPY-1 receptors in the
amygdala.
62-66 The anxiolytic effects of NPY may also
involve effects on LC function,since NPY reduces the fir-
ing of LC neurons via the NPY-2 receptor.
67 Another
brain region possibly underlying the anxiolytic action of
NPY is the hippocampus. Rats with hippocampal NPY
overexpression have reduced sensitivity to the behavioral
consequences of stress and impaired spatial learning.
68
The functional interactions between NPY and CRH may
be related to vulnerability to anxiety disorders.
69,70
Preclinical studies have shown that NPY counteracts the
anxiogenic effects of CRH and a CRH antagonist blocks
the anxiogenic effects of an NPY-Y1 antagonist.
71 Thus,
it has been hypothesized that the balance between NPY
and CRH neurotransmission is important to the expres-
sion of stress-induced anxiety and fear.
72 In general,
brain regions that express CRH and CRH receptors also
contain NPY and NPY receptors and the functional
effects are often opposite especially in the LC
72-74 amyg-
dala,
75,76 and the PAG.
77,78
An upregulated NPY system may therefore contribute
to psychological resilience.Supportive of this notion are
the findings of studies in special operations soldiers
under extreme training stress that indicate high NPY lev-
els are associated with better performance.
79 Patients with
PTSD have been shown to have reduced plasma NPY
levels and a blunted yohimbine-induced NPY increase.
80
Additionally, low levels of NPY have been found in
depressed patients,and a variety of antidepressant drugs
increase NPY levels.
81 Studies of NPY function in patients
with a spectrum of anxiety disorders is now indicated.
Galanin
Galanin is another neuropeptide shown to have anxi-
olytic properties.
82 Investigations in rats have demon-
strated that galanin administered centrally modulates
anxiety-related behaviors
83,84 and galanin receptor knock-
out mice exhibit an anxious phenotype.
85
Galanin is closely associated with ascending monoamine
pathways.Approximately 80% of noradrenergic cells in
the LC coexpress galanin. Galanin-containing neurons
originate in the LC,which innervates forebrain and mid-
brain structures including the hippocampus, hypothala-
mus,amygdala,and PFC.
86,87 Functional interactions with
the NE system is evidenced by the observation that
galanin reduces the firing rate of the LC, possibly by
stimulating the galanin-1 receptor (Gal-R1),which acts
as an autoreceptor.
88,89
These results support the idea that the noradrenergic
response to stress is associated with the release of
galanin in CeA and PFC,which may then buffer the anx-
iogenic effects of NE.Thus,the net behavioral response
due to stress-induced NE hyperactivity may depend
upon the balance between NE and NPY and galanin
neurotransmission.This hypothesis is consistent with evi-
dence that release of neuropeptides preferentially occurs
under conditions of high neurotransmitter activity.
90,91 In
this context,it is important to assess galanin function in
subjects exposed to traumatic stress, and patients with
PTSD and other anxiety disorders. Galanin and NPY
receptor agonists may represent novel targets for
antianxiety drug development.
Serotonin
There is emerging evidence that serotonin neuronal func-
tion may be related to vulnerability to anxiety disorders,
particularly in the context of adverse life events.The key
question is what aspects of serotonin function are most
involved.Preclinical studies of transgenic mice have pro-
vided important clues to the answers to this question.The
behavioral phenotype of serotonin (5-hydroxytrytamine)
5-HT1A knockout mice includes increases in anxiety-like
behaviors.
92,93 These behaviors are mediated by post-
synaptic 5-HT1A receptors in the hippocampus,amygdala,
and cortex.
94A finding of potential clinical relevance is that
embryonic and early postnatal shutdown of 5-HT1A recep-
tor expression produces an anxiety phenotype that cannot
be rescued with restoration of 5-HT1A receptors.In con-
trast, when 5-HT1A receptor expression is reduced in
adulthood and then reinstated,the anxiety phenotype is
no longer present.
94
These results indicate that altered function of 5-HT1A
receptors early in life may produce long-term abnormal-
ities in the regulation of anxiety behaviors.A possible
mechanism related to this observation is early life stress
increases CRH and cortisol levels,which in turn down-
regulate 5-HT1A receptors resulting in lower threshold
for anxiogenic stressful life events.Alternatively,5-HT1A
receptors may be decreased on a genetic basis.Consistent
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211with at least a partial genetic diathesis is the finding that
the density of 5-HT1A receptor is reduced in depressed
patients when depressed as well as in remission.
95
Examination of 5-HT1A receptor density in patients with
anxiety disorders while ill and in remission is now indi-
cated.Drugs with full agonist effects at the postsynaptic
5-HT1A receptor may be effective anxiolytic medications
in children,adolescents,and adults with anxiety disorders.
There is also evidence that the serotonin transporter 
(5-HTT) plays a role in the vulnerability to anxiety dis-
orders.Transgenic mice with a 5-HTT knockout exhibit
an excessive anxiety phenotype.
96These mice also do not
show the expected behavioral changes following treat-
ment with selective serotonin transporter inhibitor anti-
depressant drugs.
97 A very exciting recent report found
that human subjects with a specific polymorphism of the
5-HTT gene (allele) are particularly vulnerable to
depression following the experience of adverse life
events.
98 Similar gene-environment investigations are
needed in patients with anxiety disorders.
Benzodiazepine 
Exposure to inescapable stressors produce decreases in
benzodiazepine receptor binding in the cortex,with some
studies showing a decrease in the hippocampus.
99
Neuroimaging studies reveal reduced cortical and sub-
cortical benzodiazepine receptor binding in patients with
PTSD and PD.
101-103 The findings could be related to a
downregulation of benzodiazepine receptor binding fol-
lowing exposure to the stress.Further assessment of ben-
zodiazepine receptors in other anxiety disorders,such as
GAD and SAD,is needed.
A preexisting low level of benzodiazepine receptor den-
sity or an excessive downregulation of benzodiazepine
receptors following stress may be a genetic risk factor
for the development of stress-related anxiety disorders.
Drugs with selective action at the α2 and α3 subunits of
the benzodiazepine-GABA receptor may be effective
and safe anxiolytics for stress-induced anxiety.
Testosterone
Psychological stress is associated with decreases in testos-
terone levels.
104 Physically and psychologically stressful
training exercises produce a reduction in testosterone lev-
els in elite special forces.
79 Decreased testosterone from
exposure to stress may be caused by decreased leutiniz-
ing hormone–releasing hormone (LHRH) synthesis at
the hypothalamus or leutinizing hormone (LH) secretion
in the pituitary.Alternatively,another possible mechanism
involves a recently identified hypothalamic-testicular
pathway that is independent of the pituitary,but travels
through the spinal cord.This pathway appears to mediate
the effect of CRH to decrease testosterone levels.Hence,
hypothalamic increases in CRH produced by psycholog-
ical stress may be associated with decreased testosterone
by stimulating the neural pathway that interferes with
Leydig cell function independently of the pituitary.
105
The role of testosterone in the pathophysiology of anxiety
disorders in men has scarcely been researched.There is a
recent report of reduced CSF testosterone levels in PTSD
patients,which were negatively correlated with CSF CRH
concentrations.There was no correlation between plasma
and CSF testosterone levels.
106Testosterone administration
may be helpful for male patients with low preexisting
testosterone secondary to chronic severe psychological
stress.
Estrogen
There is abundant preclinical and clinical literature
demonstrating consistent gender differences in stress
responsiveness.
107 Preclinical studies have revealed that
female rats consistently show greater increases in corti-
costerone and ACTH in response to acute and chronic
stressors. These differences have generally been attrib-
uted to activational effects of gonadal steroids on ele-
ments of the HPA axis in females.
108
Studies in human populations suggest that female sub-
jects respond with greater HPA activation to stressors
involving interpersonal concerns (social rejection) and
male subjects to achievement-oriented stressors.
107 The
role of estrogen in these differential responses remains
to be studied. Estrogen has been shown to blunt HPA
axis responses to psychological stress in postmenopausal
women
109,110 and to blunt the ACTH response to CRH in
postmenopausal women with high levels of body fat.In
addition, 8 weeks of estrogen supplementation to peri-
menopausal women blunted the systolic and diastolic
blood pressure,cortisol,ACTH,plasma epinephrine and
NE,and total body NE responses to stress.
111
Women commonly suffer more from anxiety disorders
than men.Women also appear to be more sensitive to the
effects of traumatic stress.One survey found that 31% of
women and 19% of men develop PTSD when exposed to
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major trauma.
112 However, the role of estrogen in the
development of PTSD and other anxiety disorders has not
been extensively investigated. On the basis of the data
reviewed above,short-term increases in estrogen follow-
ing stress exposure might be beneficial because of its abil-
ity to blunt the HPA axis and noradrenergic response to
stress.However,long-term stress-related elevation in estro-
gen might be detrimental because of the estrogen-induced
decreases in the 5-HT1A receptor number and function.
Neurochemical response patterns related to
resilience and vulnerability to extreme stress
The above section identifies several possible mediators of
the psychobiological response to extreme stress and how
each may contribute,alone or through functional interac-
tions,to resilience or vulnerability to anxiety disorders.The
finding that many of these measures have important func-
tional interactions is supportive of the concept of devel-
oping a more integrative measure.One prediction is that
individuals in the highest quartile for measures of HPA
axis,CRH,LC-NE,and estrogen activity and the lowest
quartile for DHEA, NPY, galanin, testosterone, and 5-
HT1A receptor and benzodiazepine receptor function will
have an increased risk for anxiety disorders.In contrast,a
resilient profile will be characterized by individuals with
the highest measures of DHEA, NPY, galanin, testos-
terone,and 5-HT1A receptor and benzodiazepine receptor
function and the lowest levels of HPA,CRH,and LC-NE
activity.The mediators of the stress response identified in
this review are not meant to be an exhaustive or definitive
list.For example,glutamate and neurotrophic factors,such
as brain-derived neurotrophic factor (BDNF),and neu-
ropeptides,such as substance P and cholecystokinin,could
have been included.Longitudinal community-based sur-
veys of the effects of extreme stress on the development
of anxiety disorders should be considered to determine
whether markers such as those above or others can be uti-
lized to develop a measure of stress-related neurochemi-
cal response patterns that will be of predictive value.
Psychological characteristics of resilience and
neural mechanisms of reward, 
fear conditioning, and social behavior
In recent years,significant advances have been made in
understanding how the brain regulates reward and moti-
vation (hedonia,optimism,learned helpfulness),learns,
remembers, and responds to fear (effective behaviors
despite fear), and develops adaptive social behaviors
(altruism,bonding,teamwork).The neural mechanisms
that mediate these functions are relevant to how an indi-
vidual responds to extreme stress and may account, at
least in part,for the character traits reviewed above that
relate to resilience and vulnerability to anxiety disorders.
Regulation of reward
The proper functioning reward pathways and hedonic
tone in the context of chronic stress and an unrewarding
environment may be critical to maintaining optimism,
hopefulness,and a positive self concept following expo-
sure to extreme stress.Reward systems in resilient indi-
viduals may be either hypersensitive to reward or resis-
tant to change despite chronic exposure to neglect and
abuse.
Mesolimbic dopamine pathways have been shown in
reward,motivation,and hedonic tone.The firing pattern
of ventral tegmental area (VTA) neurons are sensitive
readouts of reward expectations in nonhuman primates.
Dopamine neurons increase when rewards occur with-
out being predicted or better than predicted.The neu-
rons show no change when rewards occur as predicted
and decreased activity when rewards are omitted or less
than predicted.
113 Functional interactions among gluta-
mate,NMDA receptors,dopamine,and dopamine recep-
tors are critical to the proper functioning of reward cir-
cuits. The medial prefrontal cortex (mPFC) receives
glutamatergic input from the amygdala and sends gluta-
matergic projections to the NAc and the VTA.Electrical
stimulation of the mPFC is thought to be rewarding
because it causes glutamate release in the VTA and
dopamine release in the NAc. In contrast, the drug of
abuse,phencyclidine,is rewarding due to its antagonism
of NMDA-type glutamate receptors in the NAc and
mPFC.
114
Genetic factors may contribute to sensitivity to the behav-
ior effects of dopamine-enhancing drugs.There may be an
endophenotype related to resistance to anhedonia and
hopelessness in the face of stress.
115 Increasing dopamine
function in the NAc, orbitofrontal cortex, and the VTA
and NMDA receptor blockade in the NAc and mPFC may
enhance sensitivity to reward.Therefore,psychostimulants,
dopamine reuptake inhibitors, monoamine oxidase B
(MAO-B) inhibitors (selegiline),dopamine receptor ago-
nists (pramipexole), and NMDA receptor antagonists(memantine) may be useful for treating anhedonia and
hopelessness resulting from traumatic stress exposure.
There have been almost no studies of the functioning of
reward-related neurochemistry and neural circuitry in anx-
iety disorders. Such investigations should be conducted
and may contribute to our understanding of stress-induced
anhedonia and its relationship to the development of anx-
iety disorders.
Neural mechanisms of anxiety and fear
Fear conditioning
In many patients with anxiety disorders,especially those
with PTSD and PD,fear conditioning causes vivid recall
of memories of traumatic events,autonomic hyperarousal,
and even flashbacks elicited by sensory and cognitive
stimuli associated with prior traumas. Consequently,
patients may begin to avoid these stimuli in their every-
day life or a numbing of general emotional responsive-
ness may ensue.Resilience to the effects of severe stress
may be characterized by the capacity to avoid over-
generalizing specific conditioned stimuli to a larger con-
text (as seen in GAD), reversible storage of emotional
memories,and facilitated extinction.
Fear conditioning is conceptualized as a form of associa-
tive learning in which subjects come to express fear
responses to neutral conditioned stimuli (CS),which are
paired with aversive unconditioned stimuli (US).As a
consequence of this pairing,the CS acquire the ability to
elicit a spectrum of behavioral,autonomic,and endocrine
responses that normally would only occur in the context
of danger.Fear conditioning can be adaptive and enable
efficient behavior in dangerous situations.The individual
who can accurately predict threat can engage in the
appropriate behaviors in the face of danger.However,in
patients with anxiety disorders, specific environmental
features (CS) may be linked to the traumatic event (US),
such that reexposure to a similar environment produces
a recurrence of symptoms of anxiety and fear. Patients
with anxiety disorders often generalize these cues and
experience a continuous perception of threat to the point
that they become conditioned to context.A chronic state
of anxiety ensues.
The neural circuitry that mediates fear-conditioning phe-
nomena has been well worked out. Cue-specific CS are
transmitted to the thalamus by external and visceral
pathways.Afferents then reach the lateral amygdala via
two parallel circuits.A rapid subcortical path directly
from the dorsal (sensory) thalamus and a slower regu-
latory cortical pathway encompassing primary
somatosensory cortices, the insula, and anterior cingu-
late/PFC. Contextual CS are projected to the lateral
amygdala from the hippocampus and perhaps the BNST.
The long loop pathway indicates that sensory informa-
tion relayed to the amygdala undergoes substantial
higher level processing,thereby enabling assignment of
significance, based upon prior experience, to complex
stimuli.
A variety of behavioral and electrophysological data has
led LeDoux and colleagues to propose a model to explain
how neural responses to the CS and US in the lateral
amygdala could influence long-term potentiation
(LPT)–like changes that store memories during fear con-
ditioning.This model proposes that calcium entry through
NMDA receptors and voltage-gated calcium channels
(VGCCs) initiates the molecular processes to consolidate
synaptic changes into long-term memory.
116 Short-term
memory requires calcium entry only through NMDA
receptors and not VGCCs.
This hypothesis leads to several predictions that may
have relevance to psychological responses to stress and
vulnerability to anxiety disorders.It suggests that block-
ing NMDA receptors in the amygdala during learning
should impair short- and long-term fear memory.This
has been demonstrated in rodents.
117-119 Valid human
models of fear conditioning and the availability of the
NMDA receptor antagonist, memantine, should permit
this hypothesis to be tested clinically. If memantine
impairs the acquisition of fear in humans, it may have
utility in the prevention and treatment of anxiety disor-
ders such as PTSD.Blockade of VGCCs appear to block
long-term but not short-term memory.
120Therefore,clin-
ically available calcium channel blockers such as vera-
pamil and nimodipine may be helpful in diminishing the
intensity and impact of recently acquired fear memory
and be relevant to the treatment of anxiety disorders.
Consolidation
The discussion above has focused primarily upon the
neural mechanisms related to the coincident learning of
the US-CS association in the lateral amygdala.However,
there is significant evidence that a broader neural cir-
cuitry underlies fear memory. Studies using inhibitory
avoidance learning procedures have been used to sup-
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fear learning,but,in addition,can modulate the strength
of memory storage in other brain structures.
121
A variety of neurotransmitters and neuropeptides influ-
ence consolidation of memory for inhibitory avoidance
training.Infusions of drugs affecting GABA,opioid,glu-
cocorticoid,and muscarinic acetycholine receptors into the
basolateral amygdala (BLA) have dose- and time-depen-
dent effects on memory consolidation.
121 NE infused
directly into the BLA after inhibitory avoidance training
enhances memory consolidation indicating that the degree
of activation of the noradrenergic system within the amyg-
dala by an aversive experience may predict the extent of
the long-term memory for the experience.
122
Activation of CRH receptors in the BLA by CRH
released from the CeA facilitates stress effects on mem-
ory consolidation.As reviewed above, there are impor-
tant functional interactions between CRH and NE sys-
tems,including a role in memory consolidation.Memory
enhancement produced by CRH infusions in the hip-
pocampus are blocked by propranolol and the nora-
drenergic toxin DSP-4,suggesting CRH through a presy-
naptic mechanism stimulates NE release in the
hippocampus.
123
These data support the concept that CRH interacts with
the noradrenergic system via an interaction with gluco-
corticoids to consolidate traumatic memories.Individuals
with excessive stress-induced release of CRH,cortisol,and
NE are likely to be prone to the development of indelible
traumatic memories and associated reexperiencing symp-
toms.Administration of CRH antagonists,glucocorticoid
receptor antagonists,and β-adrenergic receptor antago-
nists may prevent these effects in subjects vulnerable to
anxiety disorders such as PTSD,PD,and SAD.
Reconsolidation
A process in which old, reactivated memories undergo
another round of consolidation has been termed recon-
solidation.
124-126 Repeated reactivation of these memories
may serve to strengthen the memories and facilitate long-
term consolidation.
127,128 Each time a traumatic memory is
retrieved,it is integrated into an ongoing perceptual and
emotional experience and becomes part of a new memory.
Moreover,recent preclinical studies indicate that both con-
solidated memories for auditory fear conditioning,which
are stored in the amygdala,
129 hippocampal-dependent
contextual fear memory,
124 and hippocampal-dependent
memory associated with inhibitory avoidance
125 are sensi-
tive to disruption upon reactivation by administration with
a protein synthesis inhibitor directly into the amygdala and
hippocampus, respectively.The reconsolidation process
results in a reactivated memory trace,which returns to a
state of lability and must undergo consolidation once more
if it is to remain in long-term storage.This process has
enormous clinical implications ranging from a greater
understanding of traumatic remembrance to neural mech-
anisms affected by psychotherapy.
The reconsolidation process involves NMDA receptors,
β-adrenergic receptors,and requires cyclic AMP response
element binding protein (CREB) induction.
130 NMDA
receptor antagonists and β-receptor antagonists impair
reconsolidation.
127,131The effect of the β-receptor antago-
nist, propranolol, is greater after memory reactivation
than when administered immediately after initial training.
These results suggest that reactivation of memory initi-
ates a cascade of intracellular events that involve both
NMDA receptor and β-receptor activation in a fashion
similar to postacquisition consolidation.
This remarkable lability of a memory trace,which permits
a reorganization of an existing memory in a retrieval envi-
ronment, provides a theoretical basis for both psy-
chotherapeutic and pharmatherapeutic intervention for
anxiety disorders exacerbated by traumatic stress expo-
sure.Administration of β-receptor and NMDA receptor
antagonists shortly after the initial trauma exposure as
well as after reactivation of memory associated with the
event may reduce the strength of the original traumatic
memory.The effects of efficacious psychotherapies on
memory reconsolidation should be investigated.
Extinction
Extinction is a process defined by a reduction in the con-
ditioned fear responses.It forms the basis for exposure-
based psychotherapies for the treatment of a variety of
anxiety disorders,particularly those characterized by pho-
bic behaviors.Individuals who show an ability to quickly
attenuate learned fear through a powerful and efficient
extinction processes may be less vulnerable to the devel-
opment of anxiety disorders.They may also be less sus-
ceptible to the effects of intermittent exposure to fear
stimuli,which can reinstate fear-conditioned learning.
Considerable advancement has been made in our under-
standing of the neural circuitry mediating extinction.It
has been established that the mPFC plays an important
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blocks recall of fear extinction,
132,133 indicating that the
mPFC might store long-term extinction memory.An inad-
equate level of activation of the mPFC after extinction
might lead to persistent fear responses.
134 Individuals with
the capacity to function well following states of high fear
may be characterized by potent mPFC inhibition of
amygdala responsiveness.In contrast,patients with anxi-
ety disorders,such as PTSD,may exhibit depressed ven-
tral mPFC activity,which correlated with increased auto-
nomic arousal after exposure to traumatic reminders.
135
We recently showed that PTSD patients had increased
left amygdala activation during fear acquisition and
decreased mPFC/anterior cingulate activity during
extinction (Bremner JD et al,unpublished data).Similar
abnormalities may exist in other anxiety disorder
patients, most notably PD, and deserve further study. It
has been proposed that potentiating NMDA receptors
using the glycine agonist, D-cycloserine, may facilitate
the extinction process when given in combination with
behavioral therapy in patients with anxiety disorders.
136
The neural basis of social behavior
As reviewed previously, characteristics associated with
resilience include those related to altruism, optimism,
social interaction, and the capacity to attract and use
support provided by others.
3-5Therefore,understanding
the neural basis of altruism and other forms of adaptive
social behavior may be relevant to a better conceptual-
ization of the psychobiology of resilience.
Preclinical studies have used several rodent model systems
to increase our knowledge of how the brain processes
social information and regulates social behavior.
137 Perhaps
the most informative model pertinent to the clinical situ-
ation is the oxytocin knockout mouse and the study of the
neurobiology of social behaviors in prairie and montane
voles. Oxytocin and vasopressin appear to play crucial
roles in the social behavior of prairie voles.These peptides
increase the amount of time a vole spends socially engaged
and involved in the formation of the pair bond.The dif-
ferences in social behavior are explained by the regional
expression of these peptides in brain.Prairie voles,which
are more socially active and monogamous,have high lev-
els of oxytocin receptors in the NAc and BLA relative to
montane voles.
138 Similarly,prairie voles have high densi-
ties of the vasopressin-la receptor in the ventral pallidum
and medial amygdala compared with montane voles.
Infusion of vasopressin has different effects in the two
voles;prairie voles increase social interaction and montane
voles increase nonsocial behaviors such as autogroom-
ing.
139The neural mechanisms responsible for the effects
of oxytocin and vasopressin on social behavior are thought
to involve the some of the same circuitry (NAc and ven-
tral pallidum) as that involved in reward-related behavior.
This suggests that activation of these brain regions during
social interactions may facilitate the reinforcement of
social behavior.
Highly resilient individuals have exceptional abilities to
form supportive social attachments even in the context
of largely unrewarding environments. In contrast,
patients prone to anxiety disorders,especially those with
SAD, may be characterized by impairments in neural
circuitry mediating responses to reward and social inter-
action.Clinical research studies utilizing neural imaging
techniques are now capable of assessing this circuitry in
patients with anxiety disorders.
Future research directions
Examination of the neural circuits of reward,fear condi-
tioning,extinction,and social behavior reveal that several
brain structures are involved in more than one circuit.
2
This is most striking for the amygdala, NAc, and the
mPFC.The amygdala has been most prominently identi-
fied as a critical structure in fear-conditioning studies;
however,it also has a major role in reward mechanisms.
The NAc is implicated in both reward and social behav-
iors and the mPFC is a component of all three circuits.
These observations raise many intriguing questions perti-
nent to our understanding of anxiety disorders.For exam-
ple, does a particular level of amygdala function in fear
conditioning relate in a predictable way to its function in
the reward system? Does the finding of increased amyg-
dala responsiveness to fear stimuli in anxiety disorders
suggest that amygdala dysfunction will also be apparent in
the study of reward in these disorders? The redundancy in
the circuits mediating reward and social behavior,espe-
cially involving the NAc,suggest a functional interaction
between these two circuits.When both systems are func-
tioning well, positive social behaviors are reinforced.
However, an inability to experience reward due to an
impaired circuit may result in unrewarding social experi-
ences,deficient social competence,and social withdrawal.
This may be related to the neurobiological basis of SAD.
Most neuroimaging studies in patients with anxiety dis-
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reward,and social behavior circuits in isolation and not
in relation to each other.
This analysis suggests that assessment of the functional
relationship among these circuits,including the associ-
ated neurochemical modulation, may be important in
providing a more comprehensive and precise under-
standing of the contribution of these circuits to resilience
and vulnerability to anxiety disorders.Such studies might
identify crucial distinctions in the neural circuitry and
neurochemistry specific to the different anxiety disorders.
Ultimately,such work will be relevant to the discovery of
more specific therapeutic approaches to these conditions.
The opportunity now exists to identify the genetic fac-
tors that contribute to the vulnerability to stress-related
anxiety disorders.The recent identification of functional
polymorphisms for the GR,
140 the α2C adrenergic recep-
tor subtype,
141 and for NPY synthesis
142 indicates the kind
of opportunities that now exist to investigate the genetic
basis of the adaptive and maladaptive neurochemical
response pattern to stress.
Investigation of the genetic basis of the neural mecha-
nisms of reward, fear conditioning, and social behavior
is now commencing. There have been several recent
advances in understanding the genetic contribution and
molecular machinery related to amygdala-dependent
learned fear.A gene encoding gastrin-releasing peptide
(Grp) has been identified in the lateral amygdala.Mice
with Grp receptor (GRPR) knockout have enhanced
and prolonged fear memory for auditory and contextual
cues, indicating that the Grp signaling pathway may
serve as an inhibitory feedback constraint on learned
fear.
143 The work further supports the role of GABA in
fear and anxiety states
144 and suggests the genetic basis
of vulnerability to anxiety may relate to GRP, GRPR,
and GABA.A recent investigation in twins supports a
genetic contribution to fear conditioning.
145 Genetic
mechanisms affecting social affiliative behavior that may
involve the vasopressin-la receptor,which can be evalu-
ated in clinical populations.
146 Healthy subjects with the
5-HTT polymorphism that has been associated with
reduced 5-HT expression and function and increased
risk of depression following adverse life events
98 exhibit
increased amygdala neuronal activity in response to
fear-inducing stimuli.
147 These preclinical and clinical
data suggest that multidisciplinary studies that use neu-
rochemical,neuroimaging,and genetic approaches have
the potential to clarify the complex relationships among
genotype,psychobiological responses to stress,and vul-
nerability to anxiety disorders. ❏
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La psicobiología de la resiliencia y de la 
vulnerabilidad en los trastornos de ansiedad:
consecuencias para la prevención y el 
tratamiento
Gran parte de la investigación de la neurobiología de
los trastornos de ansiedad en humanos se ha cen-
trado en las anomalias psicopatológicas de los pacien-
tes con trastornos de ansiedad. Sin desconocer que
esta línea de investigación es obviamente impor-
tante, se requiere de más estudios para clarificar la
psicobiología de la resiliencia en el estrés extremo. El
estudio de la psicobiología de la resiliencia tiene la
capacidad potencial de identificar mediadores neu-
roquímicos, neuropéptidos y hormonales de vulne-
rabilidad y resiliencia en el estrés severo. Además se
puede aclarar la importancia de los mecanismos neu-
rales de recompensa y motivación, la sensibilidad al
miedo y el comportamiento social para rasgos de
carácter asociados con riesgo y resistencia en los tras-
tornos de ansiedad. Estas áreas de investigación
deberían conducir a mejores métodos diagnósticos,
nuevos enfoques en la prevención y nuevos objetivos
para el descubrimiento de fármacos ansiolíticos.
Psychobiologie de la résilience et vulnérabilité
aux troubles anxieux : implications pour la
prévention et le traitement
Une grande partie de la recherche sur la neurobio-
logie des troubles anxieux humains s’est axée sur les
anomalies psychopathologiques des patients atteints
de troubles anxieux. Bien que cette ligne de
recherche soit à l’évidence importante, il faut plus
d’investigations pour élucider la psychobiologie de
la résilience au stress extrême. Potentiellement,
l’étude de la psychobiologie de la résilience peut
identifier les médiateurs neurochimiques, neuro-
peptidiques et hormonaux de la vulnérabilité et de
la résilience au stress sévère. De plus, il est possible
de clarifier la pertinence des mécanismes nerveux de
récompense et de motivation, de réactivité à la peur
et de comportement social vis-à-vis des traits de
caractère associés au risque et à la résistance aux
troubles anxieux. Ces aires d’investigation devraient
conduire à l’amélioration des méthodes de diagnos-
tic, à de nouvelles approches pour la prévention et
à de nouveaux objectifs pour la découverte de médi-
caments dirigés contre l’anxiété.
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